CYDY CytoDyn Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1175680 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-171.6%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-351.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets614.7%
Debt / equity—
Current ratio0.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-212.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| SG&A expense | $7.45M | $7.26M |
| Operating income | -$38.58M | $9.66M |
| Pretax income | -$42.70M | $3.75M |
| Income tax | $0 | $0 |
| Net income | -$42.70M | $3.75M |
| EBITDA | -$38.56M | $9.68M |
| EPS (basic) | -0.03 | 0.00 |
| EPS (diluted) | -0.03 | 0.00 |
| Weighted avg. shares (diluted) | 1.29B | 1.24B |
| Balance sheet | ||
| Cash & equivalents | $11.85M | $11.90M |
| Current assets | $13.88M | $17.88M |
| Total assets | $13.97M | $18.05M |
| Current liabilities | $53.73M | $70.52M |
| Long-term debt | $38.34M | $45.35M |
| Total debt | $38.34M | $45.35M |
| Total liabilities | $123.69M | $114.09M |
| Shareholders' equity | -$109.72M | -$96.04M |
| Net debt | $26.49M | $33.45M |
| Shares outstanding | 1.37B | 1.25B |
| Cash flow statement | ||
| Operating cash flow | -$17.25M | -$8.77M |
| Investing cash flow | $0 | $0 |
| Financing cash flow | $17.20M | $10.85M |
| Depreciation & amortization | $17,000 | $18,000 |
| Stock-based compensation | $1.63M | $1.61M |
Free plan shows the latest 2 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.